Table 2 Summary of clinical trials focusing on perioperative immunotherapy combinations
From: Recent advances in therapeutic strategies for non-small cell lung cancer
Clinical trial | CheckMate-816 (Arm C) | CheckMate-816 (Arm A, terminated prematurely) | CheckMate-77Â T | AEGEAN | KEYNOTE -671 | NEOTORCH |
|---|---|---|---|---|---|---|
Phase | 3 | 3 | 3 | 3 | 3 | 3 |
Stage | IB-IIIA | IB-IIIA | II-IIIB | II-IIIB | II-IIIB | II-III |
No. patients | 358 | 215 | 452 | 800 | 786 | 404 |
Experimental arm | Nivolumab + CT 3 cycles | Nivolumab 3 cycles + ipilimumab at cycle 1 | Nivolumab + CT 4 cycles | Durvalumab + CT 4 cycles | Pembrolizumab + CT 4 cycles | Toripalimab + CT 3 cycles |
Control arm | CT alone | CT alone | CT alone | CT alone | CT alone | CT alone |
Primary endpoint | EFS, pCR, OS | EFS, pCR, OS | EFS | MPR, EFS | EFS | MPR, EFS |
MPR (%) | 36.9 vs 8.9 | 28.3 vs 14.8 | 35.4 vs 12.1 | 33.3 vs 12.3 | 30.2 vs 11.0 | 48.5 vs 8.4 |
pCR (%) | 24.0 vs 2.2 | 20.4 vs 4.6 | 25.3 vs 4.7 | 17.2 vs 4.3 | 18.1 vs 4.0 | 24.8 vs 1.0 |
Median EFS | NR (31.6-NR) vs 21.1 (14.8–42.1) | 54.8 (24.4-NR) vs 20.9 (14.2-NR) | NR (28.9-NR) vs 18.4 (13.6–28.1) | NR (31.9-NR) vs 25.9 (18.9-NR) | 47.2 (32.9-NR) vs 18.3 (14.8–22.1) | NR (NR-NR) vs 15.1 (10.6–21.9) |
2-year OS | 82.7% | 82.0% | Â | Â | 80.9% | 81.2% |